Lineage Cell Therapeutics
LCTX
LCTX
104 hedge funds and large institutions have $89.1M invested in Lineage Cell Therapeutics in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 26 increasing their positions, 24 reducing their positions, and 9 closing their positions.
Holders
104
Holders Change
-3
Holders Change %
-2.8%
% of All Funds
1.66%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
6
Increased
26
Reduced
24
Closed
9
Calls
$64K
Puts
–
Net Calls
+$64K
Net Calls Change
+$16K
Top Buyers
1 |
1
Vanguard Group
Malvern,
Pennsylvania
|
$9.81M |
2 |
2
Geode Capital Management
Boston,
Massachusetts
|
$3.27M |
3 |
3
BlackRock
New York
|
$11M |
4 |
4
Morgan Stanley
New York
|
$328K |
5 |
5
Northern Trust
Chicago,
Illinois
|
$1.42M |